Cardiogenic shock in cancer

Heart Fail Rev. 2019 Nov;24(6):997-1004. doi: 10.1007/s10741-019-09819-9.

Abstract

Cardiogenic shock (CS) is increasingly recognized in patients with malignancies, while cancer is independently associated with worse prognosis in CS. A number of conditions may lead to CS in cancer, including acute coronary syndromes, cardiomyopathy, takotsubo syndrome, myocarditis, pulmonary embolism, tamponade, and cardiac herniation. In these conditions, CS may be related to cancer itself or to cancer therapy, including surgery, chemotherapy, or radiotherapy. Given the significantly improved overall survival of patients with malignancies, the early recognition and proper management of CS in cancer become increasingly important. In the present paper, we review the available evidence on CS in patients with malignancies and highlight issues related to its management.

Keywords: Cancer; Cardiogenic shock; Chemotherapy; Radiotherapy.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Acute Coronary Syndrome / complications
  • Antineoplastic Agents / adverse effects
  • Cardiac Tamponade / complications
  • Cardiomyopathies / complications
  • Humans
  • Myocarditis / complications
  • Neoplasms / complications*
  • Neoplasms / mortality
  • Neoplasms / therapy
  • Pulmonary Embolism / complications
  • Radiotherapy / adverse effects
  • Secondary Prevention / methods*
  • Shock, Cardiogenic / chemically induced
  • Shock, Cardiogenic / diagnosis
  • Shock, Cardiogenic / etiology*
  • Shock, Cardiogenic / therapy*
  • Takotsubo Cardiomyopathy / complications

Substances

  • Antineoplastic Agents